Dynamic connectedness among climate change index, green financial assets and renewable energy markets: Novel evidence from sustainable development perspective

This paper investigates the connectedness among the climate change index, green financial assets, renewable energy markets, and geopolitical risk index from June 1, 2012 to June 13, 2022, using Quantile Vector Autoregressive (QVAR) and wavelet coherence (WC). The Total connectedness index (TCI) varies as long as the highest TCI originates in the upper quantile. We also note that the higher TCI decreases after the second wave of COVID19 and increases during the first 100 days of the Russia-Ukraine conflict. Moreover, the results show that Geopolitical risk (GPR) is a net transmitter of the climate change index during the Russian invasion of Ukraine. The green bond and clean energy markets are negatively connected to the GPR at extreme 10 th and 90 th quantiles. The wavelet coherence confirms the QVAR results that the climate change market can be a safe haven against GPR during the Russian invasion. The climate change index, green financial assets, and clean energy are strong influencers in the financial markets and are vital to international peace, reducing geopolitical risk. The study reports a few novel conclusions and implications from a sustainable development perspective.

1494P Anxiety and depression during the COVID-19 pandemic in newly diagnosed advanced cancer patients

Background: Cancer patients are at high risk of psychological problems and COVID-19 infection, which makes them even more vulnerable to mood disorders. Our objectives were to analyze the level of anxiety and depression among patients with advanced cancer during the COVID-19 pandemic and to analyze the association between sociodemographic, clinical, and psychological factors in patients with advanced cancer. Methods: A prospective, cross-sectional, multicenter study was conducted in 15 oncology departments in Spain. Patients with locally advanced unresectable or metastatic cancer who were candidates for systemic treatment were included. Patients completed demographic information and the Brief Symptom Inventory (BSI), Michel´s Uncertainty in Illness Scale (MUIS), Mental Adjustment to Cancer (MAC), and Cancer Worry Scale (CWS). Results: A total of 374 patients were recruited (April 2020-2021). The mean age was 64.2 years (34-88) and 48.7% were women. The most frequent were lung (30.7%) and colon (14.2%) cancers and most had metastases (78.6%). The most frequent therapy was chemotherapy (57.9%). The prevalence of anxiety and depression was 35% and 34%, respectively. Anxiety and depression levels were higher in women (p=0.001 and p=0.003, respectively). Patients <65 years (p=0.017) and with an oncologist-estimated survival of >18 months (p=0.033) had more anxiety symptoms. Logistic regression analysis revealed that women, patients with coping based on anxious preoccupation and hopelessness had higher risk of anxiety and depression (all, p<0.001). Conclusions: Patients with advanced cancer who start treatment during the COVID-19 pandemic experience high levels of depression and anxiety. Early diagnosis and the development of intervention strategies are needed especially in specific patient subgroups such as young women with long survival estimated times. Legal entity responsible for the study: The authors. Funding: This work was funded by FSEOM (Spanish Society of Medical Oncology Foundation). Disclosure: B. Obispo: Financial Interests, Personal, Invited Speaker: Lilly;Financial Interests, Personal, Invited Speaker: Sanofi;Financial Interests, Personal, Invited Speaker: Fresenius;Financial Interests, Personal, Invited Speaker: Rovi. R. Hernandez: Financial Interests, Personal, Advisory Role: Amgen;Financial Interests, Personal, Invited Speaker: Servier;Financial Interests, Personal, Invited Speaker: Lilly;Financial Interests, Personal, Invited Speaker: Roche;Financial Interests, Personal, Invited Speaker: Merck;Financial Interests, Personal, Invited Speaker: Ipsen. P. Cruz: Financial Interests, Personal, Invited Speaker: Bristol;Financial Interests, Personal, Advisory Board: Boehringer Ingelheim. A. Fernandez Montes: Financial Interests, Personal, Advisory Role: BMS;Financial Interests, Personal, Advisory Role: MSD;Financial Interests, Personal, Invited Speaker: MSD;Financial Interests, Personal, Invited Speaker: Servier;Financial Interests, Personal, Invited Speaker: Lilly;Financial Interests, Personal, Advisory Role: Lilly;Financial Interests, Personal, Advisory Role: AstraZeneca;Financial Interests, Personal, Invited Speaker: Pierre Fabre;Financial Interests, Personal, Invited Speaker: Merck. N. Piera Molons: Financial Interests, Personal, Invited Speaker: Grunenthal;Financial Interests, Personal, Invited Speaker: Kyowa Hakko Kirin;Financial Interests, Personal, Expert Testimony: Ordesa. V. Pacheco-Barcia: Financial Interests, Personal, Invited Speaker: Eisai;Financial Interests, Personal, Invited Speaker: Merck;Financial Interests, Personal, Invited Speaker: Bristol-Myers Squibb;Financial Interests, Personal, Invited Speaker: MSD;Financial Interests, Personal, Invited Speaker: Leo Pharma;Financial Interests, Personal, Invited Speaker: Kiowa Hakko Kyrin;Financial Interests, Personal, Invited Speaker: Grunenthal;Financial Interests, Personal, Invited Speaker: Prostakan;Financial Interests, Personal, Invited Speaker: Lilly. M.H. López de Ceballos: Financial Interests, Personal, Invited Speak r: Roche;Financial Interests, Personal, Invited Speaker: Eisai;Financial Interests, Personal, Invited Speaker: Novartis;Financial Interests, Personal, Invited Speaker: AstraZeneca. M. Antoñanzas Basa: Financial Interests, Personal, Other, Personal fees: AstraZeneca;Financial Interests, Personal, Other, Personal fees and no financial support: Novartis;Financial Interests, Personal, Other, Personal fees: Pierre Fabre;Financial Interests, Personal, Other, Personal fees and non-financial support: MSD;Financial Interests, Personal, Other, Personal fees and non-financial support: Sanofi;Financial Interests, Personal, Other, Personal fees: Pfizer. D. Lorente: Financial Interests, Personal, Invited Speaker, Advisory, travel fees: Janssen;Financial Interests, Personal, Invited Speaker, Advisory, travel fees: Sanofi;Financial Interests, Personal, Invited Speaker: Bayer;Financial Interests, Personal, Invited Speaker, Advisory, travel fees: Astellas;Financial Interests, Personal, Invited Speaker, Consultancy, travel fees: BMS;Financial Interests, Personal, Invited Speaker, Advisory: AstraZeneca;Financial Interests, Personal, Invited Speaker, Travel fees: Pfizer. A. Manzano Fernández: Financial Interests, Personal, Invited Speaker: Roche;Financial Interests, Personal, Invited Speaker: MSD;Financial Interests, Personal, Invited Speaker: Leo Pharma;Financial Interests, Personal, Invited Speaker: Sanofi;Financial Interests, Personal, Invited Speaker: AstraZeneca;Financial Interests, Personal, Invited Speaker: Rovi;Financial Interests, Personal, Invited Speaker: Pharmamar;Financial Interests, Personal, Advisory Board: Grunenthal;Financial Interests, Personal, Advisory Board: AstraZeneca. S. Hernando Polo: Financial Interests, Personal, Invited Speaker, Advisory role: Pfizer;Financial Interests, Personal, Advisory Board: GlaxoSmithKline;Financial Interests, Personal, Advisory Board: Clovis;Financial Interests, Personal, Advisory Board: Pharmamar;Financial Interests, Personal, Invited Speaker, Advisory role: AstraZeneca. M. Gonzalez Moya: Financial Interests, Personal, Invited Speaker: Bristol;Financial Interests, Personal, Invited Speaker: MSD;Financial Interests, Personal, Invited Speaker: Sanofi;Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim;Financial Interests, Personal, Invited Speaker: Roche;Financial Interests, Personal, Invited Speaker: Merck. All other authors have declared no conflicts of interest.